Caribou Biosciences, Inc.
Key Metrics
- Previous Close
- $1.64
- 52-Week Range
- $1.38 – $3.54
- Market Cap
- $172.60M
- P/E (TTM)
- —
- EPS (TTM)
- -1.08
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 1.53
- PEG Ratio
- —
- Return on Equity
- -78.27%
- Return on Assets
- -36.85%
- Gross Margin
- 0.00%
- Operating Margin
- -1690.39%
- Profit Margin
- 0.00%
- Current Ratio
- 6.49
- Debt/Equity
- 0.27
- Total Debt
- $26.66M
- Free Cash Flow
- $-59.61M
- Revenue Growth
- -43.80%
- Earnings Growth
- —
- Enterprise Value
- $86.41M
Market Snapshot
About
Caribou Biosciences, Inc. is a clinical-stage biotechnology company headquartered in Berkeley, California, developing off-the-shelf CAR-T cell therapies for the treatment of cancer. The company utilizes its proprietary CRISPR genome editing platform to develop next-generation cell therapies with improved anti-tumor activity and reduced manufacturing complexity. Caribou's lead programs target hematologic malignancies and are designed to be manufactured from healthy donor cells rather than a patient's own cells, potentially enabling faster treatment and lower costs. The company was founded by CRISPR pioneer Dr. Jennifer Doudna and has built significant intellectual property around CRISPR-based cellular therapies.